<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>34 patients aged between 17 and 62 years underwent triple valve replacement, 14 of whom exclusively with Starr-<z:e sem="disease" ids="C0152096" disease_type="Disease or Syndrome" abbrv="">Edwards</z:e> prosthesis; 25 patients were operated at Stage III and 4 at Stage IV of the NYHA classification; the operative mortality was 14%, the late mortality 21% </plain></SENT>
<SENT sid="1" pm="."><plain>The actuarial survival curve shows 66% survival at 5 years; in <z:hpo ids='HP_0000001'>all</z:hpo>, 21 good results were obtained with a follow-up ranging from 3 months to 11 years (average 41 months) </plain></SENT>
<SENT sid="2" pm="."><plain>A notable late complication specific to these patients was dysfunction of the tricuspid prosthesis; a gradient across the tricuspid prosthesis was observed in 14 postoperative catheter studies; one of these patients had to be reoperated for <z:mp ids='MP_0005048'>thrombosis</z:mp> of a Starr-<z:e sem="disease" ids="C0152096" disease_type="Disease or Syndrome" abbrv="">Edwards</z:e> tricuspid prosthesis </plain></SENT>
<SENT sid="3" pm="."><plain>Analysis of the results of this series suggests that surgery is beneficial, especially when the very precarious preoperative state of these patients is taken into consideration </plain></SENT>
</text></document>